FDA Updates Rx-to-OTC Switch List with Rextovy Naloxone Approval in June 2026

The most operationally significant entry on FDA's updated Prescription-to-Nonprescription Switch List is the June 16, 2026 reclassification of Rextovy (naloxone hydrochloride) nasal spray, 4 mg/0.25 ml, the second naloxone nasal spray to complete an Rx-to-OTC switch, following Narcan's approval under the same pathway in March 2023. For manufacturers holding or pursuing NDA supplements in the opioid-overdose space, the approval signals a consolidating OTC category with established labeling precedent.

The switch list, maintained by CDER, covers only products that have changed marketing status through a formal NDA or ANDA supplement, it does not capture the broader OTC monograph pathway, which accounts for a large share of nonprescription volume. That distinction matters for QA and regulatory leads benchmarking their own switch strategies: each entry on this list required a discrete labeling overhaul, consumer-directed IFU development, and a demonstration that the product meets 21 CFR Part 330 OTC GMP and labeling standards without prescriber intermediation.

The May 22, 2026 switch of Differin Epiduo Acne Gel (adapalene 0.1% / benzoyl peroxide 2.5%) under NDA 220736 adds a combination topical to the list, extending OTC access to patients 12 and older. Combination products switching status carry additional formulation and stability documentation requirements that single-entity switches do not, a consideration for any manufacturer tracking this approval as a comparator for their own pipeline submissions.

Across the full list, the pattern is consistent: switches cluster around allergy, ophthalmic, analgesic, and emergency-use categories where consumer self-diagnosis is well-supported by clinical data. Regulatory leads preparing switch applications should note that FDA's review of these NDAs evaluated not only efficacy and safety in self-use conditions but also label comprehension studies, a documentation requirement that feeds directly into the post-approval labeling change control process under ICH Q10-aligned quality systems.

Plant heads overseeing OTC manufacturing lines should also account for the GMP transition implications: products moving from Rx to OTC status shift from 21 CFR Part 211 Rx manufacturing standards into the OTC GMP framework, which carries distinct requirements around packaging, tamper evidence, and lot-release testing aligned to consumer-use conditions. Facilities that have not previously manufactured OTC drug products may require process validation updates and a site readiness assessment before commercial OTC production can begin.

The next measurable checkpoint for manufacturers tracking this space is whether any pending NDA supplements in the opioid-overdose or hormonal contraceptive categories, areas where FDA has signaled policy interest in expanded OTC access, advance to approval before the close of the current fiscal year.

Source: FDA CDER via FDA.gov Rx-to-OTC Switch List, August 12, 2026.